Latest:
Dr Migden on RP1 in Advanced Cutaneous Malignancies After Solid Organ Transplant
Michael R. Migden, MD, discusses efficacy data for RP1 in advanced non-melanoma skin cancer after prior solid organ transplant.
Authors
Olatunji Alese, MD
Latest:
Importance of Real-World Data in Supporting Treatment Options
Panelists discuss the insights from real-world data on the effectiveness of cabozantinib, regorafenib, and ramucirumab in second-line treatment for unresectable hepatocellular carcinoma, highlighting the differences between strict eligibility criteria and more flexible modified criteria in patient selection.
Duncan McLaren, MBBS, BSc, FRCR, FRCP
Latest:
Clinical Oncology Bridges Gaps Between Medical Oncology, Radiation Oncology, and Clinical Research: With D. Ross Camidge, MD, PhD; and Duncan McLaren, MBBS, BSc, FRCR, FRCP
Drs Camidge and McLaren discuss Dr McLaren’s journey to medical school and his experience as a clinical oncologist with expertise across disciplines.
Bradley W. Christensen, MD
Latest:
Dr Christensen on the Influence of Patient Selection for BCL-2 Inhibitor Treatment in AML
Bradley W. Christensen, MD, discusses the process of patient selection for BCL-2 induction therapy in patients with acute myeloid leukemia in accordance with their individual disease characteristics.
Jennifer M. King, MD
Latest:
Dr King on Teratoma in Residual Nonretroperitoneal Disease After Chemotherapy for Testicular Cancer
Jennifer M. King, MD, discusses results from a retrospective study on the prevalence of teratoma and active germ cell tumors in patients who have residual nonretroperitoneal disease following chemotherapy for nonseminomatous germ cell tumors, and what these findings indicate about the need for surgical resection in this patient population.